How to appeal a Premera Blue Cross atopic dermatitis (ad / eczema) denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Premera Blue Cross-specific note: BCBS licensee for Washington and Alaska (~2.4M members). Express Scripts PBM. WA OIC oversight. WA has strong mental health parity enforcement and surprise-billing protections that pre-date federal NSA.

What Premera Blue Cross's policy requires for atopic dermatitis (ad / eczema)

Cited policy: BCBS Ebglyss (Lebrikizumab) for AD PA

Age >=12 yr and >=40 kg per Sep 2024 label. Moderate-severe AD. Failure of topical therapy. Step-therapy through Dupixent typical; contraindication or AE accepted. Reauth 16 wk EASI-75 or IGA 0/1.

How Premera Blue Cross denies atopic dermatitis (ad / eczema) — and how to counter it

Where Premera Blue Cross pushes back: 1) Try Dupixent or Adbry first; 2) Insufficient evidence vs older biologics.

Counter-arguments that hold up: Ebglyss IL-13 high-affinity binding (distinct epitope from Adbry / Dupixent IL-4Rα). FDA Sep 13, 2024 ages 12+ supported by ADvocate-1 + ADvocate-2 (Silverberg NEJM 2023 — EASI-75 ~58% vs ~16% placebo at 16 wk monotherapy), ADhere (with TCS), ADore (12-17). AAD 2024 + ETFAD/EADV 2024 list IL-13 selective biologics as parallel options. Class switching after Dupixent AE (conjunctivitis, facial dermatitis) or partial response is rational.

What Premera Blue Cross typically denies for atopic dermatitis (ad / eczema)

Across Premera Blue Cross's commercial and Medicare books, denials cluster around a small number of patterns. For atopic dermatitis (ad / eczema), expect:

• WA-specific mental health parity violations
• Step therapy via Express Scripts
• Out-of-network reductions
• Specialty drug prior auth

Treatments most often denied in this category

These are the atopic dermatitis (ad / eczema) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Dupixent (AD)
• Adbry
• Ebglyss
• Nemluvio (AD)
• Cibinqo
• Rinvoq (AD)

How to submit the appeal to Premera Blue Cross

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Premera Blue Cross cited in the denial.
3. File the appeal through Premera Blue Cross's portal (members: https://www.premera.com ; providers: https://www.premera.com/wa/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In WA, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Premera Blue Cross's prior-authorization criteria by drug: Premera Blue Cross PA criteria on ApprovalHelp.